CAN10 Shows Promise in Early Studies, Supporting Planned Clinical Trial
CAN10, — Cantargia’s experimental therapy for scleroderma and myocarditis, or inflammation of the heart muscle — appears safe and effective at reducing inflammation and myocarditis in preclinical studies. The findings support plans to develop CAN10 for the treatment of these two conditions. “With preclinical proof of concept in…